The first domestic product!

Article source: Medical Rubik's Cube Info

On December 2, the official website of CDE showed that the listing application of Polatuzumab vedotin for Roche injection has been accepted by the State Food and Drug Administration.

Vibotuzumab is a first-in-class anti-CD79b ADC

Vibotuzumab mechanism of action

Vibotuzumab was first approved for marketing by the FDA (trade name: Polivy) as early as June 2019, combined with bendamustine + Rituxan (rituximab) for the treatment of patients who have received at least two previous treatments Adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

A phase Ib/II clinical trial evaluated Polivy's efficacy in 80 patients with relapsed or refractory DLBCL

It is worth noting that in August this year, the pivotal Phase III POLARIX trial of Polivy combined with R-CHP in the first-line treatment of DLBCL reached its primary endpoint